SPOTLIGHT: Gladstone inks Merck pact

The J. David Gladstone Institutes announced it will receive $3.25 million up front and unspecified milestone payments from Merck after signing a collaboration and licensing pact for the research and development of drugs to treat neurodegenerative diseases, including Alzheimer's disease, that are linked to apoE-regulated mechanisms in the body. The institute also gains new research funds. Release